229 related articles for article (PubMed ID: 38170977)
1. Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.
Schuster S; Vavra M; Wirth DAN; Kern WV
Microbiol Spectr; 2024 Feb; 12(2):e0304523. PubMed ID: 38170977
[TBL] [Abstract][Full Text] [Related]
2. Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors.
Schuster S; Kohler S; Buck A; Dambacher C; König A; Bohnert JA; Kern WV
Antimicrob Agents Chemother; 2014 Nov; 58(11):6870-8. PubMed ID: 25182653
[TBL] [Abstract][Full Text] [Related]
3. Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
Grimsey EM; Fais C; Marshall RL; Ricci V; Ciusa ML; Stone JW; Ivens A; Malloci G; Ruggerone P; Vargiu AV; Piddock LJV
mBio; 2020 Jun; 11(3):. PubMed ID: 32487753
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics Reveal Potential Natural Substrates of AcrB in Escherichia coli and Salmonella enterica Serovar Typhimurium.
Wang-Kan X; Rodríguez-Blanco G; Southam AD; Winder CL; Dunn WB; Ivens A; Piddock LJV
mBio; 2021 Mar; 12(2):. PubMed ID: 33785633
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
Mowla R; Wang Y; Ma S; Venter H
Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
[TBL] [Abstract][Full Text] [Related]
7. A Screening of Antimalarials Extends the Range of Known
Schuster S; Vavra M; Kern WV
Microb Drug Resist; 2022 Dec; 28(12):1065-1070. PubMed ID: 36255442
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
Wang Y; Mowla R; Guo L; Ogunniyi AD; Rahman T; De Barros Lopes MA; Ma S; Venter H
Bioorg Med Chem Lett; 2017 Feb; 27(4):733-739. PubMed ID: 28129976
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors.
Vargiu AV; Ruggerone P; Opperman TJ; Nguyen ST; Nikaido H
Antimicrob Agents Chemother; 2014 Oct; 58(10):6224-34. PubMed ID: 25114133
[TBL] [Abstract][Full Text] [Related]
10. Pyrrole-based inhibitors of RND-type efflux pumps reverse antibiotic resistance and display anti-virulence potential.
Mahey N; Tambat R; Kalia R; Ingavale R; Kodesia A; Chandal N; Kapoor S; Verma DK; Thakur KG; Jachak S; Nandanwar H
PLoS Pathog; 2024 Apr; 20(4):e1012121. PubMed ID: 38593161
[TBL] [Abstract][Full Text] [Related]
11. Recent advances toward a molecular mechanism of efflux pump inhibition.
Opperman TJ; Nguyen ST
Front Microbiol; 2015; 6():421. PubMed ID: 25999939
[TBL] [Abstract][Full Text] [Related]
12. Characterization of substituted piperazines able to reverse MDR in Escherichia coli strains overexpressing resistance-nodulation-cell division (RND) efflux pumps.
Casalone E; Vignolini T; Braconi L; Gardini L; Capitanio M; Pavone FS; Giovannelli L; Dei S; Teodori E
J Antimicrob Chemother; 2022 Feb; 77(2):413-424. PubMed ID: 34747445
[TBL] [Abstract][Full Text] [Related]
13. Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.
Soparkar K; Kinana AD; Weeks JW; Morrison KD; Nikaido H; Misra R
J Bacteriol; 2015 Oct; 197(20):3255-64. PubMed ID: 26240069
[TBL] [Abstract][Full Text] [Related]
14. Absence, loss-of-function, or inhibition of Escherichia coli AcrB does not increase expression of other efflux pump genes supporting the discovery of AcrB inhibitors as antibiotic adjuvants.
Ciusa ML; Marshall RL; Ricci V; Stone JW; Piddock LJV
J Antimicrob Chemother; 2022 Feb; 77(3):633-640. PubMed ID: 34897478
[TBL] [Abstract][Full Text] [Related]
15. New Multidrug Efflux Inhibitors for Gram-Negative Bacteria.
Marshall RL; Lloyd GS; Lawler AJ; Element SJ; Kaur J; Ciusa ML; Ricci V; Tschumi A; Kühne H; Alderwick LJ; Piddock LJV
mBio; 2020 Jul; 11(4):. PubMed ID: 32665275
[TBL] [Abstract][Full Text] [Related]
16. [Reserpine Is the New Addition into the Repertoire of AcrB Efflux Pump Inhibitors].
Shaheen A; Afridi WA; Mahboob S; Sana M; Zeeshan N; Ismat F; Mirza O; Iqbal M; Rahman M
Mol Biol (Mosk); 2019; 53(4):674-684. PubMed ID: 31397441
[TBL] [Abstract][Full Text] [Related]
17. Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation.
Aparna V; Dineshkumar K; Mohanalakshmi N; Velmurugan D; Hopper W
PLoS One; 2014; 9(7):e101840. PubMed ID: 25025665
[TBL] [Abstract][Full Text] [Related]
18. Phytochemicals increase the antibacterial activity of antibiotics by acting on a drug efflux pump.
Ohene-Agyei T; Mowla R; Rahman T; Venter H
Microbiologyopen; 2014 Dec; 3(6):885-96. PubMed ID: 25224951
[TBL] [Abstract][Full Text] [Related]
19. Spatial Characteristics of the Efflux Pump MexB Determine Inhibitor Binding.
Yamasaki S; Koga N; Zwama M; Sakurai K; Nakashima R; Yamaguchi A; Nishino K
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0067222. PubMed ID: 36300935
[TBL] [Abstract][Full Text] [Related]
20. Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps.
Plé C; Tam HK; Vieira Da Cruz A; Compagne N; Jiménez-Castellanos JC; Müller RT; Pradel E; Foong WE; Malloci G; Ballée A; Kirchner MA; Moshfegh P; Herledan A; Herrmann A; Deprez B; Willand N; Vargiu AV; Pos KM; Flipo M; Hartkoorn RC
Nat Commun; 2022 Jan; 13(1):115. PubMed ID: 35013254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
